EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Development of Phenyl‐substituted Isoindolinone‐ and Benzimidazole‐type Cereblon Ligands for Targeted Protein Degradation

Xueqing Nie, Yu Zhao, Hua Tang, Zhongrui Zhang, Junzhuo Liao, Chelsi M Almodovar-Rivera, Ramya Sundaresan, Haibo Xie, Le Guo, Bo Wang, Hongqing Guan, Yongna Xing und 1 weitere

ChemBioChem · 2024

DOI: 10.1002/cbic.202300685 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, 2024. Verfasst von Xueqing Nie und 12 weiteren Autor:innen. Beteiligte Einrichtung: Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA. Hauptthemen laut MEDLINE: Peptide Hydrolases, Nuclear Proteins, Phthalimides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thalidomide, pomalidomide and lenalidomide, collectively referred to as immunomodulatory imide drugs (IMiDs), are frequently employed in proteolysis‐targeting chimeras (PROTACs) as cereblon (CRBN) E3 ligase‐recruiting ligands. However, their molecular glue properties that co‐opt the CRL4 CRBN to degrade its non‐natural substrates may lead to undesired off‐target effects for the IMiD‐based PROTAC degraders. Herein, we reported a small library of potent and cell‐permeable CRBN ligands, which exert high selectivity over the well‐known CRBN neo‐substrates of IMiDs by structure‐based design. They were further utilized to construct bromodomain‐containing protein 4 (BRD4) degraders, which successfully depleted BRD4 in the tested cells. Overall, we reported a series of functionalized CRBN recruiters that circumvent the promiscuity from traditional IMiDs, and this study is informative to the development of selective CRBN‐recruiting PROTACs for many other therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peptide HydrolasesNuclear ProteinsPhthalimidesProteolysisTranscription FactorsUbiquitin-Protein LigasesImmunomodulating AgentsBenzimidazolesLigands

Stichwörter der Autor:innen

CRBNIMiDsPROTACTargeted Protein Degradation

Substanzen

phthalimidinePeptide HydrolasesNuclear ProteinsTranscription FactorsUbiquitin-Protein LigasesImmunomodulating AgentsBenzimidazolesLigandsPhthalimides

Autor:innen und Institutionen

  • Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Department of Chemistry, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Department of Oncology, UW Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, 53705, USA.

ORCID-Profile: Weiping Tang

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health
  • University of Wisconsin Carbone Cancer Center

Zitieren

APA

Nie, X., Zhao, Y., Tang, H., Zhang, Z., Liao, J., Almodovar-Rivera, C. M., Sundaresan, R., Xie, H., Guo, L., Wang, B., Guan, H., Xing, Y., & Tang, W. (2024). Development of Phenyl‐substituted Isoindolinone‐ and Benzimidazole‐type Cereblon Ligands for Targeted Protein Degradation. ChemBioChem. https://doi.org/10.1002/cbic.202300685

Vancouver

Nie X, Zhao Y, Tang H, Zhang Z, Liao J, Almodovar-Rivera CM, et al. Development of Phenyl‐substituted Isoindolinone‐ and Benzimidazole‐type Cereblon Ligands for Targeted Protein Degradation. ChemBioChem. 2024. doi:10.1002/cbic.202300685

BibTeX
@article{Nie2024,
  author = {Nie, Xueqing and Zhao, Yu and Tang, Hua and Zhang, Zhongrui and Liao, Junzhuo and Almodovar-Rivera, Chelsi M and Sundaresan, Ramya and Xie, Haibo and Guo, Le and Wang, Bo and Guan, Hongqing and Xing, Yongna and Tang, Weiping},
  title = {Development of Phenyl‐substituted Isoindolinone‐ and Benzimidazole‐type Cereblon Ligands for Targeted Protein Degradation},
  journal = {ChemBioChem},
  year = {2024},
  doi = {10.1002/cbic.202300685}
}
Kostenlos starten →